Clinical Trials | August 26, 2024
Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024
Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
Dr. Sanjay Behari, Director of Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, as the President of the Medical Assessment and Rating Board
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Subscribe To Our Newsletter & Stay Updated
